Search for cardiac calcium cycling gene mutations in familial ventricular arrhythmias resembling catecholaminergic polymorphic ventricular tachycardia
© Marjamaa et al; licensee BioMed Central Ltd. 2009
Received: 27 June 2008
Accepted: 12 February 2009
Published: 12 February 2009
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe inherited cardiac disorder caused by mutations predominantly in the ryanodine receptor (RyR2) gene. We sought to identify mutations in genes affecting cardiac calcium cycling in patients with CPVT and in less typical familial exercise-related ventricular arrhythmias.
Methods and Results
We recruited 33 consecutive patients with frequent ventricular premature complexes (VPCs) without structural heart disease and often history of syncope or sudden death in family. Sixteen of the patients featured a phenotype typical of CPVT. In 17 patients, VPCs emerged also at rest. Exercise stress test and echocardiography were performed to each patient and 232 family members. Familial background was evident in 42% of cases (n = 14). We sequenced all the coding exons of the RyR2, FKBP1B, ATP2A2 and SLC8A1 genes from the index patients. Single channel recordings of a mutant RyR2 were performed in planar lipid bilayers. Two novel RyR2 missense mutations (R1051P and S616L) and two RyR2 exon 3 deletions were identified, explaining 25% of the CPVT phenotypes. A rare variant (N3308S) with open probabilities similar to the wild type channels in vitro, was evident in a patient with resting VPCs. No disease-causing variants were detectable in the FKBP1B, ATP2A2 or SLC8A1 genes.
We report two novel CPVT-causing RyR2 mutations and a novel RyR2 variant of uncertain clinical significance in a patient with abundant resting VPCs. Our data also strengthen the previous assumption that exon 3 deletions of RyR2 should screened for in CPVT and related phenotypes.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe, autosomal dominantly inherited disorder characterized by stress-induced polymorphic ventricular tachycardias in a structurally normal heart [1–3]. Thus far, the ryanodine receptor type 2 (RyR2) and calsequestrin (CASQ2) genes have been identified to underlie the disease. Yet, many patients with clinical features comparable with CPVT harbor no apparent mutations in these genes, thus reflecting the existence of yet unidentified non-coding mutations or genetic heterogeneity of this disorder.
Mutations or variants in calstabin (FKBP1B), sarcoplasmic reticulum Ca2+-ATPase (ATP2A2) or sodium-calcium exchanger (SLC8A1) genes have until now not been reported to be associated with increased risk of human ventricular tachyarrhythmias. Although still a matter of controversy , a number of delicate in vitro studies suggest that depletion of calstabin, which normally stabilizes the RyR2 channel complex, is related to CPVT pathogenesis [3, 5, 6]. SERCA2a (Ca2+-ATPase), an ion pump located on the sarcoplasmic reticulum (SR) in a cardiac myocyte, plays a pivotal role in transporting intracellular Ca2+ ions back to the SR in the beginning of diastole. Thus far, SERCA2a encoded by the ATP2A2 gene has been the target of extensive in vitro and in vivo experiments in heart failure only [7–10], whereas a mutated cardiac sodium-calcium exchanger 1 (NCX1), the major Ca2+ ion remover in cardiac myocyte, has been shown to cause cardiac fibrillation in embryonic zebrafish hearts [11, 12].
According to several investigators, circulating catecholamines cause the abnormal activation of RyR2 channels and thus an arrhythmogenic leak of Ca2+ ions from the sarcoplasmic reticulum . However, it has been hypothesized that RyR2 mutations could lead to channel dysfunction also in the absence of sympathetic stimuli . In this study, we aimed to broaden the knowledge of disease-causing RyR2 mutations in resting and exercise-induced VPCs and to elucidate the involvement of not only RyR2, but also three other candidate genes in the pathology of ventricular tachyarrhythmias. We hypothesized that FKBP12.6, SERCA2a and NCX1, as integral proteins in cardiac Ca2+ signaling, might play a role in the pathogenesis of human ventricular arrhythmias and which defects might manifest with clinical features resembling CPVT.
Patients and controls
We recruited 33 consecutive symptomatic patients referred to Helsinki University Hospital for genetic studies of cardiac ion channel disorders because of frequent ventricular premature complexes (VPCs) occurring during exercise and consecutive VPCs, history of syncope and/or sudden juvenile death in family. None had apparent structural heart disease or prolonged QT interval. A total of 16 patient featured arrhythmias typical of CPVT in the exercise stress test. The remaining 17 subjects had frequent VPCs and often salvos of VPCs also at rest, thus differing from CPVT phenotype. A health enquiry, a 12-lead resting ECG, an exercise stress test, a cardiac ultrasonography and 24-hour ambulatory ECG recording were registered from each index patient. If over ten VPCs were evident in the exercise stress test of patient's first degree relatives, the clinical examinations including 12-lead resting ECG, exercise stress test and cardiac ultrasonography were extended to available second-degree relatives. A total of 232 relatives were clinically evaluated in the course of the study. History regarding the age of onset, episodes of syncopal spells and occurrence of sudden juvenile (≤ 40 years) death in the patient's first and second degree relatives were collected. The control DNA samples of 300 apparently healthy blood donors were provided by the Finnish Red Cross Blood Service. An informed consent was obtained from each patient and the Ethics Committee of the department approved the study.
We sequenced all the 105 coding exons and exon-intron boundaries of RyR2 (NM_001035) gene using ABI 3730 Automatic DNA sequencer (Applied Biosystems, Foster City, MA, USA) provided by the National Public Health Institute of Finland. Reference sequences were obtained from the National Centre for Biotechnology Information (NCBI) database. The primer sequences, designed mainly by N. Tiso, and reaction conditions for PCR amplification are available by contacting the corresponding author. The previously reported 1.1 kb RyR2 exon 3 deletion was investigated using multiplex ligation-dependent probe amplification (MLPA) analysis of RyR2 exon 3 (Salsa MLPA Kit P168, MRC Holland, Amsterdam, the Netherlands) and with PCR using primers CACAGAACAGGACCAAGTTAGAGG (forward) in intron 2 and CATTACCTTCCTGACACACTTCAT (reverse) in intron 3 of the RyR2 gene . When present, the architecture of the deletion was investigated in more detail by DNA sequencing. A functional candidate gene approach was applied to probands that failed to present RyR2 mutations. These indexes were additionally screened for variations in the exonic regions of FKBP1B (NM_004116), ATP2A2 (NM_170665) and SLC8A1 (NM_021097) genes coding for the integral proteins in cardiac Ca2+ signaling. CPVT caused by mutations in the CASQ2 gene is proposed to follow the autosomal recessive inheritance, while the disease phenotype in our patients with a familial disorder, followed autosomal dominant pattern. In addition, sequencing of the CASQ2 gene was excluded from the study protocol because our previous study on CASQ2 failed to detect any rare variants in Finnish CPVT patients . Primer sequences and the conditions for sequencing the three genes are obtainable by contacting the authors. Detection of observed allelic RyR2 variants in family members and 300 healthy controls was achieved by denaturing High Performance Liquid Chromatography (dHPLC, WAVE Nucleic Acid Fragment Analysis System HSM 3500A). Direct sequencing confirmed the genomic variations leading to divergent chromatogram profiles. The detection of ATP2A2 T982M in the relatives and controls was achieved by restriction analysis utilizing the Lwel enzyme (Fermentas International Inc, Burlington, Ontario, Canada).
In vitroelectrophysiological studies
RyR2 N3308S mutagenesis was performed with QuikChange II XL mutagenesis kit (Stratagene, La Jolla, CA, USA) using cassettes of hRyR2 subcloned into pBlueScript vector. Mutated fragments of hRyR2 were cloned back into full-length pCMV5/hRyR2 with FseI and NheI. HEK293 cells were co-transfected with 10 μg of pCMV5/hRyR2 and an equal molar amount of pCMV5/FKBP12.6 per T175 flask using calcium phosphate precipitation technique.
Single channel recordings were conducted in planar lipid bilayers under voltage clamp conditions. Microsomes containing the recombinant RyR2 channels were added to the cis-chamber and fused to the lipid bilayer consisting of 3:1 phosphatidyl ethanolamine/phosphatidyl serine (Avanti Polar Lipids, Alabaster, AL, USA). Fusion was induced by adding KCl to the cis-chamber, and the created ion gradient was eliminated after fusion by perfusing the chamber with cis-solution. The bathing solutions were as follows: cis solution, 50 mM KCl, 250 mM HEPES, 125 mM TRIS, 1 mM EGTA, 0.5 mM CaCl2; trans-solution 50 mM KCl, 53 mM Ba(OH)2 and 250 mM HEPES. All experiments were carried out in pH 7.35, and free Ca2+ concentration was determined using the program CHELATOR. 20 mM CaCl2 was added sequentially to the cis-side, and the channel activity was recorded for at least 3 min in each concentrations. At the end of each experiment, ryanodine was applied to confirm the class of the channel. Data were collected using AxoScope1 (Axon Instruments, Foster City, CA, USA) and analyzed by pClamp 6 program (Axon Instruments). The open probability (P0) was identified by 50% threshold analysis.
Statistical analysis was performed with student's t-test for continuous variables and with X 2 and Fischer's exact test for dichotomous variables using the SPSS 13.0 software. P-value of < 0.05 was considered statistically significant.
Clinical Characteristics of the Affected Individuals
CPVT (Group A)
Resting VPCs (Group B)
Females, n (%)
Age at onset, y
25 ± 16 (10–64)
27 ± 18 (5–51)
Syncope, n (%)
Heart rate, bpm
60 ± 15 (38–98)
73 ± 20 (42–99)
430 ± 55 (350–550)
405 ± 55 (320–490)
420 ± 25 (380–440)
430 ± 30 (380–450)
Exercise stress test
Threshold heart rate, bmp
127 ± 30 (87–184)
Consecutive VPCs, n
4 ± 6 (0–15)
1 ± 1 (0–5)
24 hour ECG recording
560 ± 800 (0–2670)
13800 ± 11100 (224 – 33200)
Consecutive VPCs, n
1 ± 1 (0–3)
5 ± 6 (0–24)
Familial occurrence, n (%)
Affected relatives, n (%)
SD in family, n (%)
Molecular genetic studies
Identification of RyR2missense mutations
The S616L mutation (Figure 3B) occurred in a female adolescent with exercise-induced syncopal spells since the age of twelve. Resting ECG showed a partly ectopic rhythm, and exercise stress test revealed polymorphic VPCs in a series of several beats. The mutation appeared to arise de novo as the parents of the index featured no pathological alterations in their exercise stress tests nor carried the RyR2 S616L.
In the group B, a novel RyR2 variation N3308S was discovered, but it was also detectable in one of the 600 control alleles (Figure 3C). The proband was a 34-year-old woman first presenting with palpitations and presyncopal episodes due to right ventricular outflow tract arrhythmias. Holter recordings uncovered over 20,000 predominantly single VPCs, but also bigeminial cycles and salvos up to four successive beats. The coronary angiography showed normal coronary arteries. The father of the index patient carried the variant but was not available for clinical evaluation. Two of the three descendants reported episodes of syncope and carried the same variant, yet their exercise stress tests with less than ten single monomorphic VPCs were judged to be within normal range.
Identification of RyR2exon 3 deletions
An exon 3 deletion, approximately 1.1 kb in size, was identified in two (13%) separate CPVT families. In Family D (Figure 3), the 33-year old index patient featured syncopal spells and frequent bidirectional VPCs during exercise at the time of diagnosis. His son, sister and niece featured a similar symptomatic CPVT phenotype. During follow-up of over 25 years, the index patient's son and sister showed paroxysmal atrial fibrillation. The sister also featured sinusbradycardia and atrioventricular conduction abnormalities, whereas only bradycardia was observed in her affected daughter. Apart from the ascending aorta dilatation (up to 57 mm) in the index patient's sister, none of the affected subjects showed major structural cardiovascular abnormalities. The analyses of the available DNAs revealed a 1.1 kb deletion of the RyR2 gene (c.168-301_c.273+722del1128) eliminating the highly conserved exon 3.
In the Family E (Figure 3), the index patient aged 39 years featured presyncopal spells, atrial fibrillation, bradycardia and multifocal VPCs up to runs of ventricular tachycardia upon exercise stress test. In the follow-up, he showed increased trabeculation of the left ventricle suggestive of non-compaction cardiomyopathy. His son featured polymorphic VPCs upon exercise in the absence of atrial fibrillation. A molecular analysis of the RyR2 exon 3 deletion revealed the previously reported  1.1 kb base deletion (c.168-228_c.273+793del1126) in these two patients of Family E. Both types (Family D, Family E) of genomic RyR2 deletions, although slightly different in their nature, are predicted to result in an identical in-frame deletion of 35 amino acids (p.Asn57-Gly91) from the RyR2 protein.
Other genes affecting cardiac calcium signaling
Screening for mutations in FKBP1B and SLC8A1 genes did not reveal any amino-acid alterations. A novel, conserved polymorphism T982M in the ATP2A2 gene was detectable in four (12%) individuals, two in both subgroups, and it was also identifiable in 10 of the 291 (3%) control individuals (p = 0.07).
In vitroelectrophysiological studies
Discussion and conclusion
Despite marked progress in understanding the pathogenesis of inherited ventricular arrhythmias, the molecular genetics of CPVT and frequent ventricular premature complexes without structural heart disease is incompletely known. In the present study, two CPVT families carried a corresponding in-frame RyR2 exon 3 deletion that has recently been characterized by Bhuiyan et al in two kindred of exercise-related ventricular arrhytmias, atrial arrhythmias, conduction defects and left ventricular dysfunction . Previously, it was shown that the genomic deletion of the RyR2 exon 3 occurred as a result of a Alu-repeat mediated polymerase slippage during chromosomal replication . Neither of the families in the present study featured consistent structural abnormalities suggesting that the deleted RyR2 exon 3 may underlie a spectrum of a purely electric CPVT disorder to a more complex disorders as shown previously . Characterization of the large RyR2 exon 3 deletion independently in altogether four unrelated families with CPVT-related disorders thus far suggests that this region may be of notable importance in the pathogenesis of inherited arrhythmia disorders.
In the present study, four (25%) out of the 16 probands featuring typical CPVT carried a disrupted RyR2 gene. In our previous studies, a RyR2 defect has been evident in an average of 40% of CPVT patients [18, 16] similarly to other patient populations . As we sequenced the 105 exons of the RyR2 gene and analyzed the DNAs for exon 3 deletions, our study suggests existence of non-coding intron mutations, other large yet unidentified genomic deletions, alterations in the regulatory units or genetic heterogeneity of the disorder. Combining present data to our previous studies, RyR2 alterations explain 35% of the CPVT phenotype in the Finnish probands (n = 26) of which 2 out of 9 (22%) appeared to be de novo mutations. The low frequency of de novo mutations calls for systematic cardiovascular examinations for all first degree relatives. In addition, the identified RyR2 S616L and R1051P missense mutations are expected to extend the N-terminal hot-spot region of the RyR2 gene which further challenges the method of targeted mutational analysis in which only previously mutation positive exons are sequenced.
Molecular genetic approaches should be applied in gaining further understanding in familial VPCs that occur also in resting conditions. Recently, several in vitro studies have questioned the occurrence of arrhythmias in CPVT merely in the presence of adrenergic stimulus [14, 19]. In our study, only one index showing resting VPCs carried a variant in the RyR2 gene. According to the proposed criteria for high risk right ventricular outflow tract – arrhythmias , this phenotype with extremely frequent VPCs and a history of syncope was of malignant nature. However, the asparagine substitution to serine at position 3308 maintains the polarity of the amino acid and results in a neutral replacement. In addition, the N3308S was detected in one of the 300 apparently healthy controls. The single channel experiments carried out in planar lipid bilayers did not show enhanced sensitivity of the mutant channel to the cytosolic Ca2+ under basal conditions. Collectively, the evidence of the causal role of this variant is unconvincing and suggests that the RyR2 N3308S is an innocent variant despite its rare occurrence in the Finnish population. However, a search for the variant in patients with a similar phenotype may be justifiable in other populations.
Despite the lack of convincing disease-causing RyR2 mutations in our patients with VPCs at rest, the occurrence of syncopal spells and the proportion of familial occurrence (38% vs. 41%) did not differ between the CPVT and resting VPC phenotype. Furthermore, the similar incidence of sudden juvenile death among the first and second degree relatives of the two groups suggests that even this phenotype with resting VPCs may be malignant. Elucidating the genetic background in this heterogeneous group is fundamental so that the malignant forms of the disorder could be identified. In the present study, the limited sample size precludes any definitive statements of the occurrence of rare mutations in these candidate genes in other study populations. In addition, the lack of information concerning the in vitro functional properties of the mutant RyR2 S616L and R1051P channels remains as a limitation of the present study. We conclude that mutations in FKBP1B, ATP2A2 and SLC8A1 appear subsidiary in the pathogenesis of frequent VPCs of unknown etiology in Finnish patients. RyR2 involvement in potentially malignant frequent resting VPCs requires further clarification. Large genomic RyR2 deletions involving exon 3 provide a target for future genetic studies in disorders resembling CPVT.
Dr. Andrew R. Marks is acknowledged for providing the technical facilities and resources for the in vitro electrophysiological studies. Ms Hanna Nieminen, Ms Saara Nyqvist, Mrs Susanna Tverin, Mrs Tuula Soppela, Mrs Hanna Ranne and Ms Anetta Wronska are thanked for skilful technical assistance. The study was financially supported by Sigrid Juselius Foundation, the Finnish Academy, Finska Läkaresällskapet and Biomedicum Helsinki Foundation.
- Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, Kainulainen K, Kere J, Keto P, Kontula K, Toivonen L: Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol. 1999, 34 (7): 2035-2042. 10.1016/S0735-1097(99)00461-1.View ArticlePubMedGoogle Scholar
- Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, et al: Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002, 106 (1): 69-74. 10.1161/01.CIR.0000020013.73106.D8.View ArticlePubMedGoogle Scholar
- Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, Landry DW, Kontula K, Swan H, Marks AR: Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation. 2004, 109 (25): 3208-3214. 10.1161/01.CIR.0000132472.98675.EC.View ArticlePubMedGoogle Scholar
- Thomas NL, George CH, Williams AJ, Lai FA: Ryanodine receptor mutations in arrhythmias: advances in understanding the mechanisms of channel dysfunction. Biochem Soc Trans. 2007, 35 (Pt 5): 946-951.View ArticlePubMedGoogle Scholar
- Wehrens XH, Lehnart SE, Huang F, Vest JA, Reiken SR, Mohler PJ, Sun J, Guatimosim S, Song LS, Rosemblit N, et al: FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell. 2003, 113 (7): 829-840. 10.1016/S0092-8674(03)00434-3.View ArticlePubMedGoogle Scholar
- Wehrens XH, Lehnart SE, Reiken SR, Deng SX, Vest JA, Cervantes D, Coromilas J, Landry DW, Marks AR: Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science. 2004, 304 (5668): 292-296. 10.1126/science.1094301.View ArticlePubMedGoogle Scholar
- Bers DM, Eisner DA, Valdivia HH: Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ Res. 2003, 93 (6): 487-490. 10.1161/01.RES.0000091871.54907.6B.View ArticlePubMedGoogle Scholar
- Schmidt AG, Haghighi K, Frank B, Pater L, Dorn GW, Walsh RA, Kranias EG: Polymorphic SERCA2a variants do not account for inter-individual differences in phospholamban-SERCA2a interactions in human heart failure. J Mol Cell Cardiol. 2003, 35 (7): 867-870. 10.1016/S0022-2828(03)00111-1.View ArticlePubMedGoogle Scholar
- Maier LS, Wahl-Schott C, Horn W, Weichert S, Pagel C, Wagner S, Dybkova N, Muller OJ, Nabauer M, Franz WM, et al: Increased SR Ca2+ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats. Cardiovasc Res. 2005, 67 (4): 636-646. 10.1016/j.cardiores.2005.05.006.View ArticlePubMedGoogle Scholar
- Lokuta AJ, Maertz NA, Meethal SV, Potter KT, Kamp TJ, Valdivia HH, Haworth RA: Increased nitration of sarcoplasmic reticulum Ca2+-ATPase in human heart failure. Circulation. 2005, 111 (8): 988-995. 10.1161/01.CIR.0000156461.81529.D7.View ArticlePubMedGoogle Scholar
- Langenbacher AD, Dong Y, Shu X, Choi J, Nicoll DA, Goldhaber JI, Philipson KD, Chen JN: Mutation in sodium-calcium exchanger 1 (NCX1) causes cardiac fibrillation in zebrafish. Proc Natl Acad Sci USA. 2005, 102 (49): 17699-17704. 10.1073/pnas.0502679102.View ArticlePubMedPubMed CentralGoogle Scholar
- Ebert AM, Hume GL, Warren KS, Cook NP, Burns CG, Mohideen MA, Siegal G, Yelon D, Fishman MC, Garrity DM: Calcium extrusion is critical for cardiac morphogenesis and rhythm in embryonic zebrafish hearts. Proc Natl Acad Sci USA. 2005, 102 (49): 17705-17710. 10.1073/pnas.0502683102.View ArticlePubMedPubMed CentralGoogle Scholar
- Kontula K, Laitinen PJ, Lehtonen A, Toivonen L, Viitasalo M, Swan H: Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc Res. 2005, 67 (3): 379-387. 10.1016/j.cardiores.2005.04.027.View ArticlePubMedGoogle Scholar
- Jiang D, Wang R, Xiao B, Kong H, Hunt DJ, Choi P, Zhang L, Chen SR: Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res. 2005, 97 (11): 1173-1181. 10.1161/01.RES.0000192146.85173.4b.View ArticlePubMedGoogle Scholar
- Bhuiyan ZA, Berg van den MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC, Alders M, Postma AV, van Langen I, Mannens MM, Wilde AA: Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features. Circulation. 2007, 116 (14): 1569-1576. 10.1161/CIRCULATIONAHA.107.711606.View ArticlePubMedGoogle Scholar
- Laitinen PJ, Swan H, Kontula K: Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms. Eur J Hum Genet. 2003, 11 (11): 888-891. 10.1038/sj.ejhg.5201061.View ArticlePubMedGoogle Scholar
- Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA: Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001, 103 (2): 196-200.View ArticlePubMedGoogle Scholar
- Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, Donarum EA, Marino M, Tiso N, Viitasalo M, et al: Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation. 2001, 103 (4): 485-490.View ArticlePubMedGoogle Scholar
- Jiang D, Xiao B, Zhang L, Chen SR: Enhanced basal activity of a cardiac Ca2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res. 2002, 91 (3): 218-225. 10.1161/01.RES.0000028455.36940.5E.View ArticlePubMedGoogle Scholar
- Viskin S, Antzelevitch C: The cardiologists' worst nightmare sudden death from "benign" ventricular arrhythmias. J Am Coll Cardiol. 2005, 46 (7): 1295-1297. 10.1016/j.jacc.2005.07.010.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/10/12/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.